166 related articles for article (PubMed ID: 35182276)
41. Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.
Alfarsi LH; Elansari R; Toss MS; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 Jan; 173(1):93-102. PubMed ID: 30306428
[TBL] [Abstract][Full Text] [Related]
42. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.
Hopp TA; Weiss HL; Parra IS; Cui Y; Osborne CK; Fuqua SA
Clin Cancer Res; 2004 Nov; 10(22):7490-9. PubMed ID: 15569979
[TBL] [Abstract][Full Text] [Related]
43. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
Dietrich D; Krispin M; Dietrich J; Fassbender A; Lewin J; Harbeck N; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Spyratos F; Foekens JA; Lesche R; Martens JW
BMC Cancer; 2010 Jun; 10():247. PubMed ID: 20515469
[TBL] [Abstract][Full Text] [Related]
44. Differential association of ESR1 and ESR2 gene variants with the risk of breast cancer and associated features: A case-control study.
Ghali RM; Al-Mutawa MA; Al-Ansari AK; Zaied S; Bhiri H; Mahjoub T; Almawi WY
Gene; 2018 Apr; 651():194-199. PubMed ID: 29414691
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting.
Sieuwerts AM; Lyng MB; Meijer-van Gelder ME; de Weerd V; Sweep FC; Foekens JA; Span PN; Martens JW; Ditzel HJ
Mol Oncol; 2014 Dec; 8(8):1679-89. PubMed ID: 25081647
[TBL] [Abstract][Full Text] [Related]
46. Diverse associations between ESR1 polymorphism and breast cancer development and progression.
Ding SL; Yu JC; Chen ST; Hsu GC; Hsu HM; Ho JY; Lin YH; Chang CC; Fann CS; Cheng CW; Wu PE; Shen CY
Clin Cancer Res; 2010 Jul; 16(13):3473-84. PubMed ID: 20570923
[TBL] [Abstract][Full Text] [Related]
47. Association of five single nucleotide polymorphisms at 6q25.1 with breast cancer risk in northwestern China.
Zhou L; He N; Feng T; Geng T; Jin T; Chen C
Am J Cancer Res; 2015; 5(8):2467-75. PubMed ID: 26396922
[TBL] [Abstract][Full Text] [Related]
48. Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer.
Rangel LB; Taraba JL; Frei CR; Smith L; Rodriguez G; Kuhn JG
Breast Cancer Res Treat; 2014 Dec; 148(3):571-80. PubMed ID: 25395315
[TBL] [Abstract][Full Text] [Related]
49. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.
West NR; Milne K; Truong PT; Macpherson N; Nelson BH; Watson PH
Breast Cancer Res; 2011; 13(6):R126. PubMed ID: 22151962
[TBL] [Abstract][Full Text] [Related]
50. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer.
Bertucci F; Finetti P; Viens P; Birnbaum D
Cancer Lett; 2014 Dec; 355(1):70-5. PubMed ID: 25218596
[TBL] [Abstract][Full Text] [Related]
51. Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer.
Kok M; Koornstra RH; Mook S; Hauptmann M; Fles R; Jansen MP; Berns EM; Linn SC; Van 't Veer LJ
Breast; 2012 Dec; 21(6):769-78. PubMed ID: 22738860
[TBL] [Abstract][Full Text] [Related]
52. The Role of ESR1 Gene Polymorphic Markers in the Development of Breast Cancer and Resistance to Tamoxifen Therapy.
Lukina SS; Burdennyy AM; Zavarykina TM; Riabchikov DA; Kazubskaya TP; Kruglova MP; Loginov VI
Bull Exp Biol Med; 2021 Jan; 170(3):350-355. PubMed ID: 33452979
[TBL] [Abstract][Full Text] [Related]
53. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
54. A relative ordering-based predictor for tamoxifen-treated estrogen receptor-positive breast cancer patients: multi-laboratory cohort validation.
Zhou X; Li B; Zhang Y; Gu Y; Chen B; Shi T; Ao L; Li P; Li S; Liu C; Guo Z
Breast Cancer Res Treat; 2013 Dec; 142(3):505-14. PubMed ID: 24253811
[TBL] [Abstract][Full Text] [Related]
55. Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.
Linderholm B; Bergqvist J; Hellborg H; Johansson U; Linderholm M; von Schoultz E; Elmberger G; Skoog L; Bergh J
Med Oncol; 2009 Dec; 26(4):480-90. PubMed ID: 19130322
[TBL] [Abstract][Full Text] [Related]
56. Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer.
Madeira M; Mattar A; Logullo AF; Soares FA; Gebrim LH
BMC Cancer; 2013 Sep; 13():425. PubMed ID: 24047421
[TBL] [Abstract][Full Text] [Related]
57. Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study.
Sieuwerts AM; Ansems M; Look MP; Span PN; de Weerd V; van Galen A; Foekens JA; Adema GJ; Martens JW
Breast Cancer Res; 2010; 12(6):R103. PubMed ID: 21122099
[TBL] [Abstract][Full Text] [Related]
58. Relationships of physical and breast cancer phenotypes with three single-nucleotide polymorphisms (rs2046210, rs3757318, and rs3803662) associated with breast cancer risk in Japanese women.
Kawada K; Taira N; Mizoo T; Suzuki Y; Kajiwara Y; Hatono M; Tsukioki T; Kochi M; Abe Y; Nishiyama K; Iwamoto T; Ikeda H; Shien T; Doihara H; Ishihara S; Kawai H; Kawasaki K; Ishibe Y; Ogasawara Y; Toyooka S
Breast Cancer; 2021 Mar; 28(2):478-487. PubMed ID: 33185851
[TBL] [Abstract][Full Text] [Related]
59. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
60. PTEN protein expression in postmenopausal steroid receptor positive early breast cancer patients treated with adjuvant tamoxifen.
Milovanovic Z; Dzodic R; Susnjar S; Plesinac-Karapandzic V; Juranic Z; Tatic S
J BUON; 2011; 16(1):46-51. PubMed ID: 21674849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
